• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Transphorm Inc. (Amendment)

    7/25/23 4:19:21 PM ET
    $TGAN
    Semiconductors
    Technology
    Get the next $TGAN alert in real time by email
    SC 13D/A 1 brhc20056310_sc13da.htm SC 13DA

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No. 4)*

    Transphorm, Inc.
    (Name of Issuer)

    Common Stock, $0.0001 par value
    (Title of Class of Securities)

    89386L100
    (CUSIP Number)

    Christopher Lee, Esq.
    Kohlberg Kravis Roberts & Co. L.P.
    30 Hudson Yards
    New York, New York 10001
    Telephone: (212) 750-8300
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    July 21, 2023
    (Date of Event Which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because §240.13d-1(e), 240.13d-1(f) or 240.13d-1(g) check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 89386L100
    13D
     
    1
    NAMES OF REPORTING PERSONS
     
     
    KKR Phorm Investors L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    24,724,468
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    24,724,468
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,724,468
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    39.8%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    2

    CUSIP No. 89386L100
    13D
    1
    NAMES OF REPORTING PERSONS
     
     
    KKR Phorm Investors GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    24,724,468
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    24,724,468
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,724,468
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    39.8%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    3

    CUSIP No. 89386L100
    13D
    1
    NAMES OF REPORTING PERSONS
     
     
    KKR Group Partnership L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    24,724,468
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    24,724,468
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,724,468
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    39.8%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    4

    CUSIP No. 89386L100
    13D
    1
    NAMES OF REPORTING PERSONS
     
     
    KKR Group Holdings Corp.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    24,724,468
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    24,724,468
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,724,468
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    39.8%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     

    5

    CUSIP No. 89386L100
    13D
    1
    NAMES OF REPORTING PERSONS
     
     
    KKR Group Co. Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    24,724,468
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    24,724,468
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,724,468
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    39.8%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     

    6

    CUSIP No. 89386L100
    13D
    1
    NAMES OF REPORTING PERSONS
     
     
    KKR & Co. Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    24,724,468
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    24,724,468
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,724,468
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    39.8%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     

    7

    CUSIP No. 89386L100
    13D
    1
    NAMES OF REPORTING PERSONS
     
     
    KKR Management LLP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    24,724,468
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    24,724,468
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,724,468
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    39.8%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    8

    CUSIP No. 89386L100
    13D
    1
    NAMES OF REPORTING PERSONS
     
     
    Henry R. Kravis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    24,724,468
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    24,724,468
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,724,468
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    39.8%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    9

    CUSIP No. 89386L100
    13D
    1
    NAMES OF REPORTING PERSONS
     
     
    George R. Roberts
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    24,724,468
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    24,724,468
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,724,468
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    39.8%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    10

    Explanatory Note

    This Amendment No. 4 (“Amendment No. 4”) to Schedule 13D relates to the shares of common stock, $0.0001 par value (the “Common Stock”), of Transphorm, Inc., a Delaware corporation (the “Issuer”), and amends the initial statement on Schedule 13D filed by the Reporting Persons on March 13, 2020, as amended by Amendment No. 1 filed on July 21, 2020, as amended by Amendment No. 2 filed on November 8, 2021 as amended by Amendment No. 3 filed on June 3, 2022 (as amended, the “Schedule 13D”). Except as specifically provided herein, this Amendment No. 4 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not defined in this Amendment No. 4 shall have the same meanings herein as are ascribed to such terms in the Schedule 13D.

    Item 2.
    Identity and Background.

    Item 2 of the Schedule 13D is hereby amended and restated as follows:

    (a), (f) This Schedule 13D is being filed pursuant to Rule 13d-1(a) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), by:

    (i)
    KKR Phorm Investors L.P., a Delaware limited partnership;
    (ii)
    KKR Phorm Investors GP LLC, a Delaware limited liability company;
    (iii)
    KKR Group Partnership L.P., a Cayman Islands exempted limited partnership;
    (iv)
    KKR Group Holdings Corp., a Delaware corporation;
    (v)
    KKR Group Co. Inc., a Delaware corporation;
    (vi)
    KKR & Co. Inc., a Delaware corporation;
    (vii)
    KKR Management LLP, a Delaware limited liability partnership;
    (viii)
    Henry R. Kravis, a United States citizen; and
    (ix)
    George R. Roberts, a United States citizen (the persons and entities listed in items (i) through (ix) are collectively referred to herein as the “Reporting Persons”).

    KKR Phorm Investors GP LLC is the general partner of KKR Phorm Investors L.P. KKR Group Partnership L.P. is the sole member of KKR Phorm Investors GP LLC. KKR Group Holdings Corp. is the general partner of KKR Group Partnership L.P. KKR Group Co. Inc. is the sole shareholder of KKR Group Holdings Corp. KKR & Co. Inc. is the sole shareholder of KKR Group Co. Inc. KKR Management LLP is the Series I preferred stockholder of KKR & Co. Inc. Messrs. Henry R. Kravis and George R. Roberts are the founding partners of KKR Management LLP.

    Each of Joseph Bae, Scott Nuttall, Robert Lewin, Ryan Stork, and Kathryn King Sudol is a director and executive officer of KKR Group Holdings Corp. and KKR Group Co. Inc. The executive officers of KKR & Co. Inc. are Messrs. Kravis, Roberts, Bae, Nuttall, Lewin and Stork and Ms. Sudol. The directors of KKR & Co. Inc. are listed on amended and restated Annex A attached hereto, which is incorporated herein by reference (“Annex A”).

    Each of Messrs. Bae, Nuttall, and Stork and Ms. Sudol is a United States citizen. Mr. Lewin is a Canadian citizen.

    (b) The address of the business office of each of the Reporting Persons and the other individuals named in this Item 2, unless as otherwise noted below, is:

    30 Hudson Yards
    New York, New York 10001

    The address of the principal business office of Messrs. Kravis, Bae, Nuttall, Lewin, and Stork and Ms. Sudol is:

    c/o Kohlberg Kravis Roberts & Co. L.P.
    30 Hudson Yards
    New York, New York 10001

    The address of the principal business office of Mr. Roberts is:

    11

    c/o Kohlberg Kravis Roberts & Co. L.P.
    2800 Sand Hill Road, Suite 200
    Menlo Park, CA 94025

    The address of the business office of each of the individuals listed on Annex A (other than Messrs. Kravis, Roberts, Bae, and Nuttall) is listed therein.

    (c)  KKR Group Partnership L.P., KKR Group  Co. Inc., KKR & Co. Inc. and KKR Management LLP are principally engaged in being holding companies. KKR Phorm Investors GP LLC and KKR Group Holdings Corp. are principally engaged in being the general partners of their respective partnerships. KKR Phorm Investors L.P. is principally engaged in making investments.

    The present principal occupation or employment of each of Messrs. Kravis, Roberts, Bae, Nuttall, Lewin, and Stork and Ms. Sudol is as an executive of Kohlberg Kravis Roberts & Co. L.P. and/or one or more of its affiliates. The present principal occupation of each of the other individuals named in Item 2 is listed on Annex A.

    (d) During the last five years, none of the Reporting Persons or, to the best knowledge of the Reporting Persons, any of the other individuals named in this Item 2, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) During the last five years, none of the Reporting Persons or, to the best knowledge of the Reporting Persons, any of the other individuals named in this Item 2, has been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    Item 3.
    Source and Amount of Funds or Other Considerations.

    Item 3 of the Schedule 13D is hereby amended and supplemented as follows:

    On July 5, 2023, the Issuer filed a prospectus supplement setting forth the terms and conditions of its non-transferable pro rata subscription rights offering for Common Stock (the “Rights Offering”) to stockholders of record as of June 26, 2023 (the “Record Date”). Pursuant to the Rights Offering, each stockholder of record as of the Record Date received one right per share of Common Stock held, which right was exercisable for 0.07655623 of a share of Common Stock at a price of $3.30 per share (the “Subscription Right”).  Each stockholder of record as of the Record Date that fully exercised its Subscription Right also had the right to subscribe for additional shares of Common Stock that remained unsubscribed as a result of any unexercised rights. On July 21, 2023, the Issuer completed the Rights Offering whereby KKR Phorm Investors L.P. purchased 1,735,988 shares of Common Stock representing KKR Phorm Investors L.P.’s pro-rata Subscription Right, at the subscription price of $3.30 per share. The source of funds required for the $5,728,760.40 purchase price is from capital contributions from investors in KKR Phorm Investors L.P.

    Item 5.
    Interest in Securities of the Issuer.

    Items 5(a) - (c) of the Schedule 13D is hereby amended and restated as follows:

    The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5.

    (a) and (b) The Reporting Persons may be deemed to beneficially own an aggregate of 24,724,468 shares of Common Stock, which includes 312,500 shares of Common Stock underlying warrants. Such shares of Common Stock currently owned or which may be acquired in the future represent, in the aggregate, approximately 39.8% of the outstanding shares of the Issuer’s Common Stock, as calculated pursuant to Rule 13d-3 of the Securities Exchange Act of 1934, as amended.

    The percentage of beneficial ownership in this Schedule 13D is based on 61,778,807 shares of Common Stock outstanding as of July 21, 2023 as provided by the Issuer following the completion of the Rights Offering.

    12

    Each of KKR Phorm Investors GP LLC (as the general partner of KKR Phorm Investors L.P.), KKR Group Partnership L.P. (as the sole member of KKR Phorm Investors GP LLC), KKR Group Holdings Corp. (as the general partner of KKR Group Partnership L.P.), KKR Group Co. Inc. (as the sole shareholder of KKR Group Holdings Corp.), KKR & Co. Inc. (as the sole shareholder of KKR Group Co. Inc.), KKR Management LLP (as the Series I preferred stockholder of KKR & Co. Inc.), and Messrs. Kravis and Roberts (as the founding partners of KKR Management LLP) may be deemed to be the beneficial owner of the securities beneficially owned directly by KKR Phorm Investors L.P.

    The filing of this Schedule 13D shall not be construed as an admission that any of the above-listed entities or individuals is the beneficial owner of any securities covered by this Schedule 13D.

    (c) Other than as described in Item 3 of this Schedule 13D, none of the Reporting Persons has engaged in any transaction in any shares of Common Stock during the past 60 days.

    13

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: July 25, 2023
       
         
     
    KKR PHORM INVESTORS L.P.
         
     
    By:
    KKR Phorm Investors GP LLC, its general partner
         
     
    By:
    /s/ Christopher Lee
       
    Name: Christopher Lee
       
    Title: Assistant Secretary
         
     
    KKR PHORM INVESTORS GP LLC
         
     
    By:
    /s/ Christopher Lee
       
    Name: Christopher Lee
       
    Title: Assistant Secretary
         
     
    KKR GROUP PARTNERSHIP L.P.
         
     
    By:
    KKR Group Holdings Corp., its general partner
         
     
    By:
    /s/ Christopher Lee
       
    Name: Christopher Lee
       
    Title: Secretary
         
     
    KKR GROUP HOLDINGS CORP.
         
     
    By:
    /s/ Christopher Lee
       
    Name: Christopher Lee
       
    Title: Secretary
         
     
    KKR GROUP CO. INC.
         
     
    By:
    /s/ Christopher Lee
       
    Name: Christopher Lee
       
    Title: Secretary
         
     
    KKR & CO. INC.
         
     
    By:
    /s/ Christopher Lee
       
    Name: Christopher Lee
       
    Title: Secretary


     
    KKR MANAGEMENT LLP
         
     
    By:
    /s/ Christopher Lee
       
    Name: Christopher Lee
       
    Title: Assistant Secretary
         
     
    HENRY R. KRAVIS
         
     
    By:
    /s/ Christopher Lee
       
    Name: Christopher Lee
       
    Title: Attorney-in-fact
         
     
    GEORGE R. ROBERTS
         
     
    By:
    /s/ Christopher Lee
       
    Name: Christopher Lee
       
    Title: Attorney-in-fact


    Annex A

    Directors of KKR & Co. Inc.

    The following sets forth the name and principal occupation of each of the directors of KKR & Co. Inc., whose address (unless otherwise specified in the Schedule 13D) is c/o KKR & Co. Inc., 30 Hudson Yards, New York, New York, 10001. Each of such persons is a citizen of the United States other than Arturo Gutiérrez Hernández, who is a citizen of Mexico, Xavier B. Niel, who is a citizen of France, Evan T. Spiegel, who is a citizen of the United States and France, and Matthew R. Cohler, who is a citizen of the United States and Malta.

    Name
    Principal Occupation
    Henry R. Kravis
    Co-Executive Chairman of KKR & Co. Inc.
       
    George R. Roberts
    Co-Executive Chairman of KKR & Co. Inc.
       
    Joseph Y. Bae
    Co-Chief Executive Officer of KKR & Co. Inc.
       
    Scott C. Nuttall
    Co-Chief Executive Officer of KKR & Co. Inc.
       
    Adriane M. Brown
    Managing Partner of Flying Fish Partners
       
    Matthew R. Cohler
    Former General Partner of Benchmark
       
    Mary N. Dillon
    President and Chief Executive Officer of Foot Locker, Inc.
       
    Arturo Gutiérrez Hernández
    Chief Executive Officer of Arca Continental, S.A.B. de C.V.
       
    Dane E. Holmes
    Chief Executive Officer, Co-Founder, and Chairman of Eskalera Inc.
       
    Xavier B. Niel
    Founder and Chairman of the Board of Iliad SA
       
    Patricia F. Russo
    Retired, Former Chief Executive Officer of Alcatel-Lucent
       
    Robert W. Scully
    Retired, Former Member of the Office of the Chairman of Morgan Stanley
       
    Evan T. Spiegel
    Co-Founder and Chief Executive Officer of Snap Inc.



    Get the next $TGAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TGAN

    DatePrice TargetRatingAnalyst
    6/15/2022$9.00 → $6.50Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $TGAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Kkr Phorm Investors L.P. sold $124,501,037 worth of shares (24,411,968 units at $5.10) (SEC Form 4)

    4 - Transphorm, Inc. (0001715768) (Issuer)

    6/20/24 4:30:24 PM ET
    $TGAN
    Semiconductors
    Technology

    PRESIDENT AND CEO Parikh Primit returned 489,310 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Transphorm, Inc. (0001715768) (Issuer)

    6/20/24 4:05:22 PM ET
    $TGAN
    Semiconductors
    Technology

    Chief Financial Officer Mcaulay Cameron returned 182,048 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Transphorm, Inc. (0001715768) (Issuer)

    6/20/24 4:05:17 PM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    SEC Filings

    View All

    SEC Form 15-12G filed by Transphorm Inc.

    15-12G - Transphorm, Inc. (0001715768) (Filer)

    7/1/24 9:01:49 AM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form EFFECT filed by Transphorm Inc.

    EFFECT - Transphorm, Inc. (0001715768) (Filer)

    6/21/24 12:15:13 AM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form EFFECT filed by Transphorm Inc.

    EFFECT - Transphorm, Inc. (0001715768) (Filer)

    6/21/24 12:15:04 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Renesas Completes Acquisition of Transphorm

    Accelerates Wide Bandgap Product Offering and Introduces 15 New GaN-Based Winning Combination Reference Designs Renesas Electronics Corporation ("Renesas" TSE:6723), a premier supplier of advanced semiconductor solutions, today announced that it has completed the acquisition of Transphorm, Inc. (NASDAQ:TGAN), a global leader in gallium nitride (GaN) power semiconductors, as of June 20, 2024. With the closing of the acquisition now completed, Renesas will immediately start offering GaN-based power products and related reference designs to meet the rising demand for wide bandgap (WBG) semiconductor products. This press release features multimedia. View the full release here: https://www.bu

    6/20/24 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Demonstrates a Bidirectional SuperGaN Power Supply with New Reference Design for E-Mobility and Energy/Industrial Markets

    300 W DC-to-DC Battery Charger Board Showcases Key Capability of GaN Technology Necessary to Advance E-Mobility Applications Transphorm, Inc. (NASDAQ:TGAN), the global leader in robust GaN power semiconductors, today announced the release of a new 300 W DC-to-DC GaN reference design for 2- and 3-wheeled electric vehicle battery chargers. The TDDCDC-TPH-IN-BI-LLC-300W-RD design uses TP65H150G4PS 150 mOhm SuperGaN® FETs in a robust TO-220 package to power a high performing, high efficiency energy harvesting and distribution battery charging system. The new board notably demonstrates one of the most anticipated value propositions of a GaN power supply: bidirectionality. This capability indic

    6/11/24 3:00:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm's SuperGaN at PCIM 2024: Surpassing SiC and e-mode GaN Capabilities in High Power Systems

    Lower Losses, Higher Performance Delivered by Transphorm's Normally-off d-mode Platform Enables Electric Vehicle, Datacenter/AI, and Other Multi-market Power Systems, Along with Groundbreaking GaN Product Innovations Transphorm, Inc. (NASDAQ:TGAN), the global leader in robust GaN power semiconductors, announced today that its PCIM 2024 showcase will underscore its ability to outperform competitive wide bandgap technologies in higher power systems. For example, Transphorm's normally-off d-mode SuperGaN® platform delivers higher electron mobility resulting in lower crossover losses versus Silicon Carbide—making it more a cost-effective, higher performing solution for various electric vehicl

    5/20/24 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Transphorm downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Transphorm from Buy to Neutral and set a new price target of $6.50 from $9.00 previously

    6/15/22 7:40:43 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Financials

    Live finance-specific insights

    View All

    Renesas Completes Acquisition of Transphorm

    Accelerates Wide Bandgap Product Offering and Introduces 15 New GaN-Based Winning Combination Reference Designs Renesas Electronics Corporation ("Renesas" TSE:6723), a premier supplier of advanced semiconductor solutions, today announced that it has completed the acquisition of Transphorm, Inc. (NASDAQ:TGAN), a global leader in gallium nitride (GaN) power semiconductors, as of June 20, 2024. With the closing of the acquisition now completed, Renesas will immediately start offering GaN-based power products and related reference designs to meet the rising demand for wide bandgap (WBG) semiconductor products. This press release features multimedia. View the full release here: https://www.bu

    6/20/24 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Announces Fiscal 2024 Third Quarter Results and Provides Business Update

    Transphorm, Inc. (NASDAQ:TGAN)—a global leader in GaN, the future of next generation power systems, announced today its financial results for the third quarter of its fiscal year ending March 31, 2024 ("Q3 Fiscal 2024"). On January 10, 2024, Transphorm announced that it entered into a definitive agreement to be acquired by a subsidiary of Renesas Electronics Corporation. The transaction values Transphorm at approximately $339 million. Key Business Highlights Reported total revenue of $4.7 million for Q3 Fiscal 2024, an increase of 4.0% over the same quarter last year and a decrease of 6.8% from the prior quarter. Product revenue was $3.2 million in the quarter, a decrease of 20%

    2/20/24 4:05:00 PM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Announces Fiscal 2024 Second Quarter Results and Provides Business Update

    - Reports Second Quarter Year-Over-Year Revenue Grew 37% to $5.0 Million as Gross Margin Increased by 11.5% to 23% - Product Revenue Increased to $3.55 Million, Up 18% Over the Prior Quarter - Recently Engaged BofA Securities, Inc. to Act as Financial Advisor in Company's Strategic Review to Enhance Stockholder Value - Company to Host Webcast Today at 5:00 p.m. EST to Review Quarterly Results and Provide a Business Update Transphorm, Inc. (NASDAQ:TGAN)—a global leader in GaN, the future of next generation power systems, announced today its financial results for the second quarter of its fiscal year ending March 31, 2024 ("Q2 Fiscal 2024"). Primit Parikh, Transphorm's CEO and Co-Fo

    11/9/23 4:05:00 PM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Transphorm Inc.

    SC 13D/A - Transphorm, Inc. (0001715768) (Subject)

    6/20/24 4:30:51 PM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form SC 13G/A filed by Transphorm Inc. (Amendment)

    SC 13G/A - Transphorm, Inc. (0001715768) (Subject)

    2/14/24 10:15:50 AM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form SC 13G/A filed by Transphorm Inc. (Amendment)

    SC 13G/A - Transphorm, Inc. (0001715768) (Subject)

    2/13/24 1:41:50 PM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Leadership Updates

    Live Leadership Updates

    View All

    Transphorm Announces Appointment of Company Co-founders as Chief Executive Officer and Board Chair

    Follows Retirement of CEO and as part of the Company's Planned Succession Strategy Transphorm, Inc. (NASDAQ:TGAN)—a pioneer in and global supplier of high-reliability, high-performance gallium nitride (GaN) power conversion products, announced that its Board of Directors has appointed Dr. Primit Parikh as President and Chief Executive Officer of the Company and as a member of the Board. The Board also appointed Dr. Umesh Mishra to serve as Chair of the Board. Both of these appointments are effective May 15, 2023. Dr. Parikh and Dr. Mishra, who co-founded the Company's main operating subsidiary Transphorm Technology Inc., succeed Mario Rivas, who has served as the Company's Chief Executi

    5/15/23 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Appoints Six Company Leaders

    Company Veterans and Industry Leaders to Drive Next Phase of Growth Transphorm, Inc. (NASDAQ:TGAN)—a pioneer in and a global supplier of high reliability, high performance gallium nitride (GaN) power conversion products—announced today the appointment of six company leaders. The roles are being filled by company veterans as well as newly hired experts, strategically building out Transphorm's executive bench. The collective sales, operations, engineering, and product marketing skillsets brought by these individuals will contribute to Transphorm's business growth and customer support strategies as the company responds to a rapidly rising demand for high voltage GaN power semiconductors acros

    10/27/22 9:00:00 AM ET
    $TGAN
    Semiconductors
    Technology